A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

NCT03742102 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

243

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Neoplasms

Interventions

DRUG: Durvalumab
DRUG: Capivasertib
DRUG: Oleclumab
DRUG: Paclitaxel
DRUG: Trastuzumab deruxtecan
DRUG: Datopotamab deruxtecan

Sponsor

AstraZeneca